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In order to explore the neuroprotective and cross-
species activities of C-peptide on type 1 diabetic
neuropathy, spontaneously diabetic BB/W-rats were
given increasing doses of human recombinant C-
peptide (hrC-peptide). Diabetic rats received 10, 100,
500, or 1000g of hrC-peptide/kg body weight/
day from onset of diabetes. After 2 months of hrC-
peptide administration, 100g and greater doses
completely prevented the nerve conduction defect,
which was associated with a significant but incom-
plete prevention of neural Na+/K+-ATPase activity
in diabetic rats with 500g or greater C-peptide re-
placement. Increasing doses of hrC-peptide showed
increasing prevention of early structural abnormali-
ties such as paranodal swelling and axonal degener-
ation and an increasing frequency of regenerating
sural nerve fibers. We conclude that hrC-peptide ex-
erts a dose dependent protection on type 1 diabetic
neuropathy in rats and that this effect is probably
mediated by the partially conserved sequence of the
active C-terminal pentapeptide.
Keywords: Human C-peptide, BB/Wor-rat, diabetic neuropa-
thy, prevention.
INTRODUCTION
There is now mounting evidence demonstrating
that C-peptide has preventive and ameliorating
effects on the chronic complications of type 1
diabetes in both humans and experimental ani-
mal models [1-3].
In a recent study [4], we demonstrated the pre-
ventive and therapeutic effects of rat II C-peptide
on the acute and chronic metabolic, functional
and structural abnormalities of diabetic polyneu-
ropathy (DPN) in type 1 diabetic BB/Wor-rat.
Although, it is not clear how C-peptide exerts
these beneficial effects, recent studies suggest that
C-peptide has insulinomimetic metabolic and mi-
togenic effects [5-7]. A specific C-peptide receptor
has not yet been characterized [8]. The metabolic
effects of C-peptide include corrective effects on
nerve Na+/K+-ATPase and endothelial NO [7-
10], which has been associated with its beneficial
effects on peripheral nerve function in experi-
mental type 1 diabetic rat models and humans
[1,4,10]. C-peptide has by itself no effect on hy-
perglycemia [4,11].
It has been proposed that the mid-portion of
human C-peptide mediates all or part of its bio-
logical activity [1], since it is highly conserved in
mammalian species. On the other hand, the C-ter-
minal pentapeptide, which possesses receptor/
ligand type interaction shows the same biological
activity as the entire 31 amino acid C-peptide
[8,11]. In the present study we examined the
dose response relationship between four doses
of human recombinant C-peptide (hrC-peptide)
given by subcutaneous osmotic pumps on neural
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Na+/K+-ATPase, nerve conduction velocity
(NCV) and early structural changes in two month
diabetic BB/Wor-rats.
MATERIALS AND METHODS
Animals
Fifty prediabetic male BB/Wor-rats and ten age-
and sex-matched non-diabetes prone BB/Wor-rats
were obtained from Biomedical Research Models
(Worcester, MA, U.S.A.). All animals were main-
tained in air-filtered metabolic cages with ad
libitum access to rat chow (Wayne lab blox F-6,
Wayne Food Division, Chicago, IL, U.S.A.) and
water. Body weight and urine glucose were moni-
tored daily to ascertain the onset (76 + 4 days of
age) of diabetes, following which diabetic animals
were given daily titrated doses (0.5-3.5 I.U.) of
protamine zinc insulin (Blue Ridge Pharmaceuti-
cals, NC, U.S.A.) in order to maintain blood glu-
cose levels between 20-25mmol/1 and to prevent
ketoacidosis as previously described [4]. Blood
glucose was measured every two weeks and at
the end of the study. Immediately after onset of
diabetes, rats were randomly assigned to five
treatment groups, eight animals per group, diabet-
ic rats were either sham operated or received 10,
100, 500, or 1000xg hrC-peptide per kg/day
(Schwarz Pharma AG, Monheim, Germany). HrC-
peptide was dissolved in phosphate-buffered
saline and delivered via subcutaneously implant-
ed osmotic pumps (Alza Corporation, Palo Alto,
CA, U.S.A.). Non-diabetic control animals (n 10)
were sham operated.
Electrophysiological Studies
Nerve conduction velocity was measured at I and
2 weeks and 1 and 2 months of diabetes. It was
measured in the left sciatic-tibial nerves under
temperature controlled (35-37C) conditions [12].
The left sciatic nerve was stimulated supramaxi-
mally (8V) with square wave pulses (20Hz) at
the sciatic notch and the tibial nerve at the ankle
using an electromyography machine (5200A,
Cadwell Laboratory, Kennewick, WA, U.S.A.). The
compound evoked motor responses were ob-
tained from the first interosseous space and were
measured from stimulus artifact to onset of the M-
wave deflection [12]. EachNCV value represented
the averaging of 8 or 16 recordings and was calcu-
lated by subtracting the distal from the proximal
latency divided by the distance between the two
stimulating electrodes, givingNCV in m.sec-1.
Tissue Collection
Non-fasted animals were sacrificed with a Na-
pentobarbital overdose (100mg/kg body wt.
i.p.) and both sciatic nerves were dissected,
weighed and snap-frozen in liquid nitrogen and
stored at -70C for measurement of Na+/K+-
ATPase activity. The right sural nerve was fixed
in situ with 2.5% glutaraldehyde in 0.1M caco-
dylate buffer (pH 7.40), dissected and immersion
fixed in the same fixative overnight at 4C
and post-fixed in cacodylate buffered (0.1 M) 1%
osmium tetroxide (pH 7.40) overnight at 4C.
The sural nerve was dehydrated and single
myelinated fibers were teased in unpolymerized
Epon as previously described [4,12]. Plasma was
collected for assessment of hrC-peptide levels,
which were determined by HPLC-Electrospray
Mass Spectroscopy.
Biochemical Analysis
For assessment of Na+/K+-ATPase activity, nerve
samples were homogenized in 2ml of 0.2M su-
crose and 0.02 M Tris-HC1 at pH 7.5. Ten to 20 txl
of the homogenate was assayed enzymatically for
total ATPase activity in lml of 100mM NaC1,
10mM KC1, 2.5mM MgCI2, lmM ATP, lmM
phosphoenolpyruvate, 30mM imidazole HC1
buffer (pH 7.3), 0.15mM NADH, 50 Ixg lactate de-
hydrogenase and 30txg pyruvate kinase [13]. To
measure ouabain-inhibitable ATPase activity, 20 txl
of 25mM ouabain was added. Na+/K+-ATPase
activity was defined as the difference in activity
before and after addition of ouabain and was
expressed as pomol ADP formed per gram of
wet weight per hour. Assays were performed in
duplicates.
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Teased Fiber Examination
A mean of 168 4 myelinated fibers were teased
from each sural nerve and scored for specific
changes, providing a three dimentional assess-
ment of myelinated fiber pathology as previously
described in detail [4,12]. Representing the tem-
poral sequence and increasing severity of myeli-
nated fiber pathology, they were classified as
follows: normality, paranodal swelling, paranodal
demyelination, excessive myelin wrinkling, inter-
calated internodes, segmental demyelination,
Wallerian degeneration, and regeneration. Each
fiber was scored as to its most severe change and
expressed as a percentage of total fibers.
Statistical Analysis
The results are presented as mean + SD and the
significance of differences was calculated by
analysis of variance (ANOVA) with SPSS ver-
sion 10.0.7 software. When an overall difference
of p < 0.05 was obtained, group differences were
assessed by post hoc analysis using Scheffe’s
test. Tissue samples for biochemical and teased
fiber analysis were coded in order to mask ani-
mal identity.
RESULTS
Clinical and Metabolic Findings
HrC-peptide replacement in diabetic BB/Wor-
rat had no effects on body weights, blood
glucose levels or daily insulin requirements
(Table 1). Plasma hrC-peptide levels were pro-
gressively increased in keeping with increasing
doses (Table 1). NCV at 2 months of non hrC-
peptide replaced diabetic rats was significantly
(p <0.001) decreased to 83% of control values.
Ten tg of hrC-peptide partially (p <0.001) pre-
vented the NCV deficit, which however still
remained significantly (p < 0.05) decreased com-
pared to control rats. On the other hand, 100; 500
and 1000g of hrC-peptide replacement com-
pletely (p < 0.001) prevented the nerve conduc-
tion defect (Fig 1). Non-hrC-peptide replaced
diabetic animals showed a 58% (p < 0.01) reduc-
tion in Na+/K+-ATPase activity compared to
control rats (Fig 2). Ten and 100 pg hrC-peptide
showed no significant prevention of the Na+/
K+-ATPase defect, whereas 500 and 1000g
completely (p < 0.05) prevented the deficit in Na+/
K+-ATPase activity.
Teased Sural Nerve Fibers
Two months of diabetes revealed structural ab-
normalities of 20% (p<0.001) of sural nerve
myelinated fibers. Ten g of hrC-peptide had no
effect on the frequency of normalcy, whereas 100,
500 and 1000g showed significant prevention
(p < 0.01 for 100 txg; p < 0.001 for 500 and 1000 g)
of myelinated fiber pathology, although it was
not completely prevented when compared to con-
trol rats (Fig 3). The most profound structural
change at this stage of type 1 diabetes is the
Na+/K+-ATPase related paranodal swelling
TABLE Body weights, blood glucose levels, daily insulin requirements and hrC-peptide plasma concentrations at termination
of the study (data expressed as mean + SD) in control, sham-operated diabetic and hrC-peptide replaced diabetic BB/Wor-rats
HrC-peptide
Daily Insulin Plasma
Body Weight Blood Glucose Dose Concentration
(g) (mmol/1) (I.U/day) ng/ml
Control n 10
Sham-operated n 7
HrC-peptide 10g n 8
HrC-peptide 100g n 8
HrC-peptide 500 pg n 8
HrC-peptide 1000g n 8
427 19 5.3 0.3 0 0
324 21" 22.5 2.1" 2.2 0.8* 0
325 29*,+ 24.5 3.3*,+ 2.5 0.8*,+ 0
327 27*,t 24.3 3.3*,t 2.9 0.5*,+ 2.8 0.3*
329 19*‘+ 23.3 2.8*,+ 2.3 0.8*,+ 9.8 2.5*
339 23*,+ 23.6 3.4*,+ 2.5 0.7*,+ 31.3 13.9"
*: p < 0.001 vs age-matched non-diabetic control rats; -: No significant difference vs duration-matched sham-operated diabetic rats.
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Control Sham
NS NS
10tg 100tg 500tg
hrC-peptide
1000gg
FIGURE Motor nerve conduction velocities (MNCV’s) in
control, sham-operated diabetic and hrC-peptide replaced
BB/Wor rats at 2 months. *: p < 0.05, **: p < 0.001, vs age-
matched controls; r: p <0.001 vs duration-matched sham-
operated BB/W-rats, NS: non-significant.
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FIGURE 2 Na+/K+-ATPase activity in sciatic nerves from 2
month control, sham-operated diabetic and hrC-peptide
replaced diabetic rats. *: p <0.01, vs age-matched controls;
: p < 0.05 vs duration-matched sham-operated BB/W-rats.
[4,14]. This was increased almost 5-fold (p < 0.001)
in non-hrC-peptide replaceded diabetic rats,
but was prevented by 52 and 70% in 500 and
1000g hrC-peptide replaced animals respective-
ly (both p < 0.001; Fig 4), although these values
were not normal (p<0.001) (Fig 4). Paranodal
swelling is followed by paranodal demyelination
[4,12], which was exhibited by 1.8% of fibers in
non-hrC-peptide replaced diabetic rats (Fig 5).
Ten and 1001g of hrC-peptide had no effect
on paranodal demyelination, whereas 500 and
ioo
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*’ p<O.O1 p<O.O01
10g 100tg 500gg 1000gg
hrC-peptide
FIGURE 3 Frequencies of structurally normal myelinated
fibers in the sural nerve of control, sham-operated diabetic
and hrC-peptide replaced diabetic BB/Wor rats. *: p < 0.001,
vs age-matched control; : p<0.01, vs duration-matched
sham-operated BB/W-rats; :: p < 0.001, vs duration-matched
sham-operated BB/W-rats, NS: non-significant. The p-values
of differences between hrC-peptide replaced groups are
indicated.
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Control Sham lOl.tg
p<0.05
p<O.O01
p<O.O01
1001.tg 500gg 1000gg
hrC-peptide
FIGURE 4 Frequencies of the earliest identifiable structural
change, paranodal swelling, in control, sham-operated
diabetic and hrC-peptide replaced diabetic rats at 2 months.
*: p <0.001, vs age-matched controls, +: p <0.001, vs dura-
tion-matched sham-operated BB/W-rats. The p-values of dif-
ferences between hrC-peptide replaced groups are indicated.
1000txg fully (p<0.001) prevented paranodal
demyelination (Fig 5).
Axonal degeneration, comprised of excessive
myelin wrinkling, reflecting axonal atrophy, and
Wallerian degeneration, was increased 3-fold
(p < 0.001) in non-treated diabetic rats (Fig 6). It
was progressively prevented by increasing doses
of hrC-peptide replacement and was completely
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Control Sham 10gg 100gg 500gg 1000gg
hrC-peptide
FIGURE 5 Paranodal demyelination in 2 month control,
sham-operated diabetic, hrC-peptide replaced diabetic rats.
*: p <0.001, vs age-matched controls, +: p <0.001, vs dura-
tion-matched sham-operated diabetic BB/W-rats.
Control Sham 10tg 100g 500g
hrC-peptide
1000tg
FIGURE 7 Frequencies of regenerated myelinated fibers in
control, sham-operated diabetic and hrC-peptide replaced
diabetic rats at 2 months. ***: p < 0.001, vs age-matched con-
trols and sham-operated diabetic BB/W-rats.
10
0
Control
p<o.05 **,"
p<0.05 *,:I
sham 10.tg 100g 500gg 1000.tg
hrC-peptide
FIGURE 6 Axonal degeneration (sum of frequencies of ex-
cessive myelin wrinkling and Wallerian degeneration) in
control, sham-operated diabetic and hrC-peptide replaced di-
abetic BB/Wor- rats. *: p <0.01, **: p <0.001, vs age-matched
controls, +: p <0.05, :: p <0.01, : p <0.001, vs duration-
matched sham-operated diabetic BB/W-rats, NS: non-signifi-
cant. The p-values of differences between hrC-peptide
replaced groups are indicated.
(p <0.001) prevented by 1000 txg of hrC-peptide
(Fig 6).
Increasing doses of hrC-peptide promoted
nerve fiber regeneration in the sural nerve, the
frequencies of which were significantly (p < 0.001)
increased in 500 and 1000g replaced animals
(Fig 7).
DISCUSSION
The present data demonstrate a dose related pre-
vention of functional, metabolic and structural
abnormalities of early DPN in type 1 diabetic
BB/Wor-rats by hrC-peptide. These findings are
similar to those previously reported following re-
placement with type II rat C-peptide [4]. Similar
to the findings in this study, parameters such as
normalcy and paranodal swelling were not fully
prevented in hyperglycemic rats even with the
highest replacement dose of hrC-peptide in the
present study. We have previously suggested, by
comparing the DPN in the type 1 C-peptide defi-
cient diabetic BB/Wor-rat with that in the normal
C-peptidemic type 2 BB/Z-rat [12], that DPN in
type 1 rats is caused by a hyperglycemic compo-
nent and a C-peptide responsive component.
Since activation of the polyol pathway is also as-
sociated with these early structural changes [15]
and is not corrected by C-peptide replacement
[4], it is possible that the residual structural ab-
normalities in the present study reflect polyol-
pathway induced abnormalities similar to those
seen in the milder DPN of type 2 BB/Z-rats [12].
The prevention of the Na+/K+-ATPase defect
in diabetic peripheral nerve is in keeping with
our previous data [4] and those of others [1,9],
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and probably accounts for the prevention of
the early metabolic NCV defect, which is close-
ly associated with decreased Na+/K+-ATPase
activity [16]. Nodal changes such as axo-glial
dysjunction, paranodal demyelination and inter-
calated internodes are characteristic of type 1
DPN in human and animal models but do not
occur in type 2 DPN [12,17,18]. The complete
prevention of paranodal demyelination by 500
and 1000 pg hrC-peptide is consistent with previ-
ous findings, showing complete prevention of
the preceding axo-glial dysjunction and para-
nodal demyelination in the type 1 rat model [4].
Sugimoto et al [19] have demonstrated that the
insulin receptor co-localizes with paranodal axo-
glial junctions in peripheral nerve. We [19] and
others [20] have suggested that insulin may have
a regulatory effect on nodal tight junction integ-
rity. This is consistent with C-peptide’s insuli-
nomimetic and preventive effects on disruption
of paranodal axo-glial junctions and paranodal
demyelination. The dose related increase in
nerve fibe,r regeneration is in agreement with our
previous study [4] and is possibly related to C-
peptide’s corrective effect on IGF-1 expression in
peripheral nerve [21]. Although not examined in
the present study, C-peptide has an ameliorating
effect on endothelial NO [22]. Such a beneficial
effect on NO and microcirculation is likely to im-
prove endoneurial blood flow, hence contribut-
ing to the prevention of DPN.
The amino-acid sequence of C-peptide shows
considerable species variations [8]. It has been
suggested that the conserved midportion medi-
ates its biological effect [1]. However, this has
not been confirmed by others [8,11], who instead
have shown that the C-terminal pentapeptide is
responsible for C-peptide activity. The active C-
terminal pentapeptide differs by three amino-
acids between rat and man. In the present study
approximately 104 higher concentrations of hrC-
peptide was necessary to achieve the same ef-
fects as those reported with rat II C-peptide
(75nmol/kg body weight/day) [4], which may
be due to the only partially conserved regions
of the C-terminal which possesses the receptor/
ligand type interaction [8].
In summary the present study has shown
dose-dependent effects of hrC-peptide on early
DPN in the type 1 diabetic BB/Wor-rat, demon-
strating its preventative effect and cross-species
activity which is likely mediated by the partially
conserved sequence of the biologically active
C-terminal.
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